ArticleChinese medical journal2019
Validation of fatty liver index and hepatic steatosis index for screening of non-alcoholic fatty liver disease in adults with obstructive sleep apnea hypopnea syndrome.
Article in Chinese medical journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 35 citations in OpenAlex.
- Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study.Diabetes care · 2021Trial
- Comparison of Ketogenic Diets with and without Ketone Salts versus a Low-Fat Diet: Liver Fat Responses in Overweight Adults.Nutrients · 2021Trial
- Joint effect of hepatic steatosis index and triglyceride glucose index on cardio-renal outcomes: a real-world study.Journal of diabetes and metabolic disorders · 2026Article
- Performance of three clinical scores for steatosis and steatohepatitis and their interaction with metabolic syndrome in obese individuals.World journal of hepatology · 2026Article
- Long-term metabolic risks after thyroidectomy and thyroid hormone therapy in thyroid cancer survivors: a nationwide cohort study.Frontiers in endocrinology · 2026Article
- Surveying the features of screening strategies for non-alcoholic fatty liver disease: A scoping review.Journal of education and health promotion · 2026Review
- Platelet-derived growth factor receptor-β as a non-invasive biomarker for liver fibrosis prediction in Egyptian diabetic patients with metabolic-associated fatty liver disease.BMC gastroenterology · 2025Article
- Management of metabolic dysfunction-associated steatotic liver disease (MASLD)-An expert consensus statement from Indian diabetologists' perspective.Diabetes, obesity & metabolism · 2025Review
- Predicting metabolic dysfunction associated steatotic liver disease using explainable machine learning methods.Scientific reports · 2025Article
- Metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes: risk of heart failure.Cardiovascular diabetology · 2024Article
- Precision Non-Alcoholic Fatty Liver Disease (NAFLD) Diagnosis: Leveraging Ensemble Machine Learning and Gender Insights for Cost-Effective Detection.Bioengineering (Basel, Switzerland) · 2024Article
- Association of Obstructive Sleep Apnea with Nonalcoholic Fatty Liver Disease: Evidence, Mechanism, and Treatment.Nature and science of sleep · 2024Review
- Associations between types and sources of dietary carbohydrates and liver fat: a UK Biobank study.BMC medicine · 2023Article
- The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Utility of Indices Obtained during Medical Checkups for Predicting Fatty Liver Disease in Non-obese People.Internal medicine (Tokyo, Japan) · 2023Observational
- Assessing the clinical utility of major indices for nonalcoholic fatty liver disease in East Asian populations.Biomarkers in medicine · 2023Review
- Metabolic dysfunction-associated fatty liver disease: from basic research to clinical application.Chinese medical journal · 2022Article
- Sodium in relation with nonalcoholic fatty liver disease: A systematic review and meta-analysis of observational studies.Food science & nutrition · 2022Review
- Novel screening model of obstructive sleep apnea for snorers with suspected NAFLD undergoing liver sonography.BMC pulmonary medicine · 2021Article
- Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: a Korean Nationwide Cohort.Journal of Korean medical science · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObstructive sleep apnea hypopnea syndrome (OSAHS) is a contributing factor for non-alcoholic fatty liver disease (NAFLD). Non-invasive algorithms including fatty liver index (FLI) and hepatic steatosis index (HSI) have been used as a screening test for NAFLD in epidemiologic studies. The aim of this study is to compare the diagnostic accuracy of FLI and HSI for NAFLD detection in adults with OSAHS.
methodsWe enrolled consecutive adult subjects who were newly diagnosed with OSAHS from March 2016 to January 2018. NAFLD was diagnosed by ultrasonography. The accuracy and cut-off point of the FLI and HSI to detect NAFLD were assessed by analyzing the area under the receiver operating characteristic (AUROC) curve and the maximum Youden index analysis, respectively.
resultsThe 326 subjects were diagnosed as NAFLD according to ultrasound findings, while 105 subjects who had normal abdominal ultrasonography were grouped as controls. Both FLI and HSI values were significantly higher in patients with NAFLD compared with controls. The AUROC of FLI and HSI for predicting NAFLD was 0.802 (95% confidence interval [CI] 0.762-0.839) and 0.753 (95% CI 0.710-0.793), respectively. The AUROC of FLI was significantly higher than that of HSI (P = 0.0383). The optimal cut-off value of FLI and HSI was 60 (sensitivity 66% and specificity 80%) and 35 (sensitivity 81% and specificity 60%), respectively.
conclusionsBoth FLI and HSI can serve as screening tools for NAFLD in OSAHS adults. The FLI shows better performance in diagnosing NAFLD than HSI.
trial registrationChinese Clinical Trial Registry (No. ChiCTR-OOB-15007253), http://www.chictr.org.cn/showproj.aspx?proj=11606.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.